These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6268945)

  • 1. Structural proteins of poliovirus type 2 isolates.
    Yoneyama T; Hagiwara A; Hara M
    Microbiol Immunol; 1981; 25(6):575-83. PubMed ID: 6268945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic and biochemical characterization of poliovirus type 1 isolates of non-vaccine origin.
    Hara M; Hagiwara A; Yoneyama T; Saito Y; Shimojo H
    Microbiol Immunol; 1983; 27(12):1057-65. PubMed ID: 6328228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration in oligonucleotide fingerprint patterns of the viral genome in poliovirus type 2 isolated from paralytic patients.
    Yoneyama T; Hagiwara A; Hara M; Shimojo H
    Infect Immun; 1982 Jul; 37(1):46-53. PubMed ID: 6179881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and antigenic variation of the structural protein VP3 in serotype 1 poliovirus isolated from vaccinees.
    Cash P
    Can J Microbiol; 1988 Jun; 34(6):802-6. PubMed ID: 2849500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative biochemical studies of type 3 poliovirus.
    Minor PD
    J Virol; 1980 Apr; 34(1):73-84. PubMed ID: 6246264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral poliovirus vaccine in the United States: molecular characterization of Sabin type 3 after replication in the gut of vaccinees.
    Tatem JM; Weeks-Levy C; Mento SJ; DiMichele SJ; Georgiu A; Waterfield WF; Sheip B; Costalas C; Davies T; Ritchey MB
    J Med Virol; 1991 Oct; 35(2):101-9. PubMed ID: 1662701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in three of the four coat proteins of oral polio vaccine strain derived from type 1 poliovirus.
    Kew OM; Pallansch MA; Omilianowski DR; Rueckert RR
    J Virol; 1980 Jan; 33(1):256-63. PubMed ID: 6245231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic and biochemical characterization of poliovirus type 1 isolates.
    Hara M; Arita M; Yamazaki Z; Hagiwara A; Saito Y
    Microbiol Immunol; 1987; 31(4):327-36. PubMed ID: 3039316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee.
    Minor PD; John A; Ferguson M; Icenogle JP
    J Gen Virol; 1986 Apr; 67 ( Pt 4)():693-706. PubMed ID: 2420925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis.
    Furione M; Guillot S; Otelea D; Balanant J; Candrea A; Crainic R
    Virology; 1993 Sep; 196(1):199-208. PubMed ID: 8102826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees.
    Friedrich F
    Acta Virol; 1996 Jun; 40(3):157-70. PubMed ID: 8891097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coupled mutations in the 5'-untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications.
    Muzychenko AR; Lipskaya GYu ; Maslova SV; Svitkin YV; Pilipenko EV; Nottay BK; Kew OM; Agol VI
    Virus Res; 1991 Oct; 21(2):111-22. PubMed ID: 1661980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic and biochemical characterization of poliovirus type 2 isolated from two cases of paralytic disease.
    Fiore L; Pierangeli A; Lombardi F; Santoro R; Crainic R; Venuti A; Perez-Bercoff R
    Intervirology; 1987; 27(4):196-204. PubMed ID: 2447031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of virus polypeptide structure with attenuation of poliovirus type 1.
    Milstien JB; Walker JR; Eron LJ
    J Virol; 1977 Sep; 23(3):811-5. PubMed ID: 197272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
    Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
    J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of sequences in the 5' non-coding region on the replication of polioviruses in the human gut.
    Minor PD; Dunn G
    J Gen Virol; 1988 May; 69 ( Pt 5)():1091-6. PubMed ID: 2836553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polypeptide composition of poliovirions, naturally occurring empty capsids, and 14S precursor particles.
    Phillips BA; Fennell R
    J Virol; 1973 Aug; 12(2):291-9. PubMed ID: 4355933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term excretion of vaccine-derived poliovirus by a healthy child.
    Martín J; Odoom K; Tuite G; Dunn G; Hopewell N; Cooper G; Fitzharris C; Butler K; Hall WW; Minor PD
    J Virol; 2004 Dec; 78(24):13839-47. PubMed ID: 15564492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans.
    Kew OM; Nottay BK; Hatch MH; Nakano JH; Obijeski JF
    J Gen Virol; 1981 Oct; 56(Pt 2):337-47. PubMed ID: 6273502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.